Chemed Q2 FY26 GAAP diluted EPS climbs 43.7% to $5.13; revenue increases 8.8% to $673.3 million
CHE•Q2 results and segment performance
Chemed posted Q2 revenue of $673.3 million, up 8.8%, with GAAP diluted EPS of $5.13, up 43.7%.
- VITAS net patient revenue climbed 11.9% to $443.3 million; average daily census rose 6.1% to 23,687.
- VITAS recorded $500,000 in Medicare Cap billing limitation versus $16.4 million a year earlier; no Florida cap is expected in 2026.
- Roto-Rooter revenue increased 3.3% to $229.9 million; adjusted EBITDA was $48.5 million, essentially flat, with margin down 0.77 percentage point to 21.1%.
2026 outlook raised
Chemed raised its 2026 adjusted diluted EPS guidance to $25.00-$25.75 from $24.00-$24.75, mainly on VITAS outperformance; the Roto-Rooter outlook was unchanged.
